Q4 2024 AVITA Medical Inc Earnings Call Transcript
Key Points
- AVITA Medical Inc (AVHHL) reported a 30% increase in commercial revenue for Q4 2024 compared to the same period in 2023, driven by the adoption of RECELL GO.
- The company successfully launched PermeaDerm and received approval for RECELL GO mini, expanding its product portfolio and market reach.
- AVITA Medical Inc (AVHHL) achieved a high gross profit margin of 87.6% in Q4 2024, indicating strong operational efficiency.
- The introduction of Cohealyx, a collagen-derived dermal matrix, is expected to significantly reduce hospital stays and healthcare costs.
- The company's total addressable market (TAM) has expanded from $500 million to $3.5 billion in the US alone, reflecting its strategic growth and product diversification.
- AVITA Medical Inc (AVHHL) experienced a revenue shortfall of approximately $3 million to $4 million in Q4 2024 due to deferred purchases by key customers.
- The net loss for Q4 2024 was $11.6 million, an increase from the $7.1 million loss in the same period of 2023.
- Operating expenses increased by $1.4 million in Q4 2024 compared to the same period in 2023, primarily due to higher sales and marketing costs.
- The company faces challenges in the European market due to delays in receiving CE mark approval for RECELL GO.
- AVITA Medical Inc (AVHHL) has a significant amount of debt, with interest expenses increasing by $4.2 million year-over-year.
Good day, and thank you for standing by. Welcome to the AVITA Medical fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Jessica Ekeberg, Director of Investor Relations. Please go ahead.
Thank you, operator. Welcome to AVITA Medical's fourth quarter and full-year 2024 earnings call. Joining me on today's call are Jim Corbett, Chief Executive Officer; and David O'Toole, Chief Financial Officer. Today's earnings release and presentation are available on our website, www.avitamedical.com, under the Investor Relations section.
Before we begin, I'd like to remind you that this call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are neither promises nor guarantees and involve known and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
